In a recently published paper in the Annals of Oncology [1], Choi et al. evaluated the strength of the evidence in the literature for the association between body mass index and 20 cancers in a manner that resembles our umbrella review on the same topic [2] . We were surprised to see that there were many discrepancies between the two assessments. The current paper used a grading scheme consisting of similar criteria used in our umbrella review, but structured the grading differently without providing a justification for this choice. Our umbrella review used a grading scheme that has been extensively applied and justified in previous studies [3] , and the results for adiposity and cancer in our study were consistent with previous assessments by the World Cancer Research Fund (WCRF) and the International Agency for Research on Cancer (IARC) ( Table 1) [4, 5] . We feel that the authors' choice of grading scheme fails to correctly classify the evidence. Associations between adiposity and risk of postmenopausal breast, colon, gallbladder, gastric, liver, ovarian and thyroid cancers received weak or not significant evidence grades in the current paper in contrast to convincing evidence grades received in the previous reports [2, 4, 5] .
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There are also a number of other methodological concerns that may affect the validity of the evidence grading in the current paper. First, the authors pooled studies from several meta-analyses on the same topic (e.g. for prostate and pancreatic cancer) without acknowledging/correcting for study overlap across metaanalyses, which is substantial. Second, the authors updated existing meta-analyses by selectively adding only one newly published study without conducting a systematic literature search. Third, the authors do not report or differentiate their analysis by study design (e.g. cohort versus case-control), which may have important implications in the quality of the evidence. Fourth, several associations by cancer subsite or according to modifying factors have been omitted from the current paper (e.g. by menopausal status or hormone replacement therapy use for gynaecological malignancies). Fifth, the authors used a P-value threshold of 0.05 for Egger's regression asymmetry test as evidence for small-study effects, but this test is known to be underpowered and 0.10 is the widely accepted threshold.
In summary, IARC, WCRF and our umbrella review have rated the quality of evidence in the field of adiposity and cancer by using different methodologies, but reached similar conclusions. In contrast, we are afraid that the current paper fails to correctly classify this evidence. Letters to the editor Annals of Oncology
